A novel pathway for regulation of glucose‐dependent insulinotropic polypeptide receptor expression in β‐cells
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Glucose‐dependent insulinotropic polypeptide (GIP) is secreted postprandially and acts in concert with glucose to stimulate insulin secretion from the pancreas. Here, we describe a novel pathway for the regulation of GIP receptor (GIPR) expression within clonal β‐cell lines, pancreatic islets, and in vivo . High (25 mM) glucose was able to significantly reduce GIPR mRNA levels in INS(832/13) cells after only 6 h. In contrast, palmitic acid (2 mM) and WY 14643 (100 μM) stimulated approximate doublings of GIPR expression in INS(832/13) cells under low (5.5 mM), but not high (25 mM), glucose conditons, suggesting that fat can regulate GIPR expression via PPARα in a glucose‐dependent manner. Both MK‐886, an antagonist of PPARα, and a dominant negative form of PPARα transfected into INS(832/13) cells caused a significant reduction in GIPR expression in low, but not high, glucose conditions. Finally, in hyperglycemic clamped rats, there was a 70% reduction in GIPR expression in the islets and a 71% reduction in GIP‐stimulated insulin secretion from the perfused pancreas. Thus, evidence is presented that the GIPR is controlled at normoglycemia by the fatty acid load on the islet; however, when exposed to hyperglycemic conditions, the GIPR is down‐regulated, which may contribute to the decreased responsiveness to GIP that is observed in type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, GLP-1 and GIP mediate insulin secretion and concomitantly, insulin modulates GIP212 and GLP-1 release; the latter ocurring through the PI3K/Akt- and mitogen-activated protein kinase kinase (MAPKK or MEK)/ERK1/2 pathway.213”
From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [212]
Citations
Cites
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism
Desvergne, B. (1999) · Endocrine Reviews · doi:10.1210/er.20.5.649 · Cited by 1,251
Kulkarni, R. N., Brüning, J. C., Winnay, J. N., Postic, C., Magnuson, M. A., & Kahn, C. R. (1999) · Cell · doi:10.1016/s0092-8674(00)80546-2 · Cited by 1,148
Quantitative RT-PCR: Pitfalls and Potential
Freeman, W. M., Walker, S. J., & Vrana, K. E. (1999) · BioTechniques · doi:10.2144/99261rv01 · Cited by 1,147
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 3×
“Glucose-dependent insulinotropic polypeptide (GIP) and the proglucagon gene products glucagon-like peptide-1-( 7-37 ) (GLP-1) and GLP-1-(7-36)-amide are the major incretins that act via this endocrine system (1).”
BackgroundMethodSelf-citationHohmeier, H. E., Mulder, H., Chen, G., Henkel-Rieger, R., Prentki, M., & Newgard, C. B. (2000) · Diabetes · doi:10.2337/diabetes.49.3.424 · Cited by 917
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 4×
“Both GIPR and GLP-1 receptor null mice displayed compromised insulin secretion and therefore exhibited poor glucose tolerance to an oral glucose load (8, 9).”
BackgroundInfluentialMiyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · cited 4×
“Both GIPR and GLP-1 receptor null mice displayed compromised insulin secretion and therefore exhibited poor glucose tolerance to an oral glucose load (8, 9).”
BackgroundInfluential
Research works printed but not linked: 2
- 10.1210/en.140.1.398 · doi:10.1210/en.140.1.398 · Paper page
- 10.1042/bj3560899 · doi:10.1042/bj3560899 · Paper page
Cited by
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“Another study suggested a role for circulating free fatty acids in down-regulation of GIPR expression (Lynn et al., 2003).”
BackgroundGIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
“1), it is tempting to speculate that the lack of late-phase insulin secretion in the different groups of diabetic patients (79) might result from an enhanced desensitization and/or internalization of a normal or reduced number of GIP receptors (46).”
BackgroundThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“The molecular mechanism that supports this differential insulinotropic response in type 2 diabetes is not known, but purported prospects include downregulation in GIP receptor signaling (402, 403, 495, 670, 678) and alternative splicing of the GIP receptor in hyperglycemia (261).”
Background
Metadata
- Authors
- Lynn, F. C., Thompson, S. A., Pospisilik, J. A., Ehses, J. A., Hinke, S. A., Pamir, N., McIntosh, C. H. S., & Pederson, R. A.
- Affiliations
- University of British Columbia (CA)
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2002-11-15
- Volume
- 17
- Issue
- 1
- Pages
- 91-93
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1967225560
- Cited by
- 91
- References
- 43
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 5 · 2021: 1 · 2020: 2 · 2019: 6 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 3 · 2013: 5 · 2012: 6
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Diabetes Association
- Canada Foundation for Innovation
- Health Research Foundation
- Medical Research Council
- Killam Trusts
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, beta-cell gene expression, PPARα, palmitic acid, fatty acid regulation, hyperglycemia, insulin secretion, type 2 diabetes, Wy-14,643, MK-886, pancreatic islets
- MeSH terms
- Animals, Cell Line, Dose-Response Relationship, Drug, Fatty Acids, Gene Expression Regulation, Glucose, Islets of Langerhans, Kinetics, Models, Biological, Rats, Zucker, Receptors, Gastrointestinal Hormone, RNA, Messenger, Transcription Factors, Transcription, Genetic, Signal Transduction, Down-Regulation, Receptors, Cytoplasmic and Nuclear, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.